Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis

Author:

Spessotto Caroline Vieira1,Cavalli Hanaie2,Eboni Audred Cristina Biondo3,Machado Rafael Berlezi4,Mousquer Analara Munardi5,Palazzo Lara Both4,Finkelsztejn Alessandro4,Goncalves Marcus Vinicius Magno3,Sato Henry Koiti2,Siquineli Fabio5,Fragoso Yara Dadalti6

Affiliation:

1. Universidade Metropolitana de Santos, Brasil; Angiocorpore, Brasil

2. Instituto de Neurologia de Curitiba, Brasil

3. Centro Hospitalar Unimed, Brasil

4. Hospital de Clinicas de Porto Alegre, Brasil

5. Universidade Regional de Blumenau, Brasil

6. Universidade Metropolitana de Santos, Brasil

Abstract

ABSTRACT Objective The treatment of multiple sclerosis (MS) with disease-modifying-drugs (DMDs) is evolving and new drugs are reaching the market. Efficacy and safety aspects of the drugs are crucial, but the patients’ satisfaction with the treatment must be taken into consideration. Methods Individual interview with patients with MS regarding their satisfaction and points of view on the treatment with DMDs. Results One hundred and twenty eight patients attending specialized MS Units in five different cities were interviewed. Over 80% of patients were very satisfied with the drugs in use regarding convenience and perceived benefits. The only aspect scoring lesser values was tolerability. Conclusion Parameters for improving treatment in MS must include efficacy, safety, and patient satisfaction with the given DMD.

Publisher

FapUNIFESP (SciELO)

Subject

Neurology,Clinical Neurology

Reference7 articles.

1. A longitudinal study on fatigue, depression, and their relation to neurocognition in multiple sclerosis;Hildebrandt H;J Clin Exp Neuropsychol,2014

2. Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population;Twork S;Curr Med Res Opin,2007

3. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis;Menzin J;J Manag Care Pharm,2013

4. Fostering adherence to injectable disease-modifying therapies in multiple sclerosis;Lugaresi A;Expert Rev Neurother,2014

5. Therapy Optimization in Multiple Sclerosis: a cohort study of therapy adherence and risk of relapse;Cohen BA;Mult Scler Relat Disord,2015

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3